An experimental vaccine against Alzheimer’s disease has cleared its first
hurdle. Elan Pharmaceuticals of Dublin announced this week that the first 100
patients to receive the vaccine had not suffered any serious side effects. Some
showed an immune response. Codenamed AN-1792, the vaccine is a synthetic version
of the amyloid protein that clogs up the brains of patients. The company now
plans to test the vaccine in the US and Europe.
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features
Popular articles
Trending New Scientist articles
1
Woman with Alzheimer's starts conversing again after taking psilocybin
2
New-to-science spider builds trap that flings ants into the air
3
How menopause radically changes the brain – and what happens after
4
How some people's brains make an extraordinary recovery from stroke
5
SpaceX's secretive plans to deliver cargo to Earth from space
6
Faecal transplant makes the brains of old mice act young again
7
What’s the secret to living well beyond the average life expectancy?
8
Can prebiotics, probiotics or postbiotics help your ageing microbiome?
9
Unapproved gene therapy for boosting longevity is set to go on sale
10
We've found a mysterious substance on Titan and Pluto
